Stock Research for ADRD

ADRD

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ADRD Stock Chart & Research Data

The ADRD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ADRD Due diligence Resources & Stock Charts

The ADRD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADRD Detailed Price Forecast - CNN Money CNN View ADRD Detailed Summary - Google Finance
Yahoo View ADRD Detailed Summary - Yahoo! Finance Zacks View ADRD Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ADRD Trends & Analysis - Trade-Ideas Barrons View ADRD Major Holders - Barrons
NASDAQ View ADRD Call Transcripts - NASDAQ Seeking View ADRD Breaking News & Analysis - Seeking Alpha
Spotlight View ADRD Annual Report - CompanySpotlight.com OTC Report View ADRD OTC Short Report - OTCShortReport.com
TradeKing View ADRD Fundamentals - TradeKing Charts View ADRD SEC Filings - Bar Chart
WSJ View Historical Prices for ADRD - The WSJ Morningstar View Performance/Total Return for ADRD - Morningstar
MarketWatch View the Analyst Estimates for ADRD - MarketWatch CNBC View the Earnings History for ADRD - CNBC
StockMarketWatch View the ADRD Earnings - StockMarketWatch MacroAxis View ADRD Buy or Sell Recommendations - MacroAxis
Bullish View the ADRD Bullish Patterns - American Bulls Short Pains View ADRD Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ADRD Stock Mentions - StockTwits PennyStocks View ADRD Stock Mentions - PennyStockTweets
Twitter View ADRD Stock Mentions - Twitter Invest Hub View ADRD Investment Forum News - Investor Hub
Yahoo View ADRD Stock Mentions - Yahoo! Message Board Seeking Alpha View ADRD Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ADRD - SECform4.com Insider Cow View Insider Transactions for ADRD - Insider Cow
CNBC View ADRD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADRD - OTC Markets
Yahoo View Insider Transactions for ADRD - Yahoo! Finance NASDAQ View Institutional Holdings for ADRD - NASDAQ


Stock Charts

FinViz View ADRD Stock Insight & Charts - FinViz.com StockCharts View ADRD Investment Charts - StockCharts.com
BarChart View ADRD Stock Overview & Charts - BarChart Trading View View ADRD User Generated Charts - Trading View




Latest Financial News for ADRD


Sanofi’s Q3 Earnings: Analysts’ Estimates
Posted on Tuesday October 30, 2018

Sanofi (SNY) is one of the largest pharmaceutical companies. Since the company’s headquarters are in Paris, its reports its financial results in euros. Sanofi is set to release its third-quarter earnings on October 31. Wall Street analysts expect the EPS to be 1.71 euros on revenues of 9.32 billion euros during the third quarter.


How Novartis’s Alcon Performed in Third Quarter
Posted on Tuesday October 23, 2018

Alcon, the eye care business of Novartis AG (NVS), includes surgical products and vision care products. Alcon reported revenues of ~$1.76 billion during the third quarter of 2018, a 3% increase in year-over-year (or YoY) revenues as compared to ~$1.71 billion in the third quarter of 2017. The growth was driven by a 5% growth in operating revenues, offset by a 2% negative impact of foreign exchange.


How Novartis’s Business Segments Performed in the Third Quarter
Posted on Monday October 22, 2018

As discussed earlier, Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues. Novartis AG is the holding company providing healthcare solutions, and its business is classified into three business segments including the Innovative Medicines segment, Sandoz, and Alcon. The below chart shows the revenue performance of Novartis’s segments since the first quarter of 2017. 


Analysts’ Estimates and Ratings for Novartis in October
Posted on Thursday October 11, 2018

Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.